Tigecycline treatment of multi-drug-resistant Corynebacterium jeikeium infection in a child with relapsing and refractory acute lymphoblastic leukemia

• Published in: Pediatric blood & cancer Vol. 55; no. 2; pp. 349 - 351
• Main Authors: Dinleyici, Ener Cagri, Yargic, Zeynel Abidin, Bor, Ozcan, Kiremitci, Abdurrahman, Durmaz, Gul
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.08.2010
• Subjects: Acute lymphatic leukemia; Anti-Bacterial Agents - therapeutic use; Blood; Cancer; Catheter-Related Infections; Catheterization, Central Venous - adverse effects; Catheters; Child; Children; Corynebacterium Infections - drug therapy; Corynebacterium jeikeium; Drug Resistance, Multiple; Female; Humans; Infection; leukemia; Lymphatic leukemia; Minocycline - analogs & derivatives; Minocycline - therapeutic use; Neutropenia; Pediatrics; Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology; Recurrence; Remission Induction; Sepsis; tigecycline
• ISSN: 1545-5009; 1545-5017; 1545-5017
• DOI: 10.1002/pbc.22527

Corynebacterium jeikeium has been recognized as an important cause of infection, particularly among neutropenic patients who have central venous catheter (CVC). Routine use of tigecycline in children is not yet approved. Here in we present a child with relapsed‐refractory lymphoblastic leukemia who was successfully treated with tigecyline due to multi‐drug‐resistant C. jeikeium sepsis without removal of CVC. Our case highlights the use of tigecycline where there are no alternatives. Further studies regarding the efficacy and safety of tigecycline in pediatric patients are needed. Pediatr Blood Cancer. 2010;55:349–351. © 2010 Wiley–Liss, Inc.